Ionis Pharmaceuticals, Inc. (IONS) financial statements and ratios from SEC XBRL: revenue $0.9B (TTM), net margin -40.4%, revenue growth -40.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $943.71M |
| Revenue (TTM) | $0.9B |
| Net Margin | -40.4% |
| Operating Margin (TTM) | -68.0% |
| Revenue Growth (YoY) | -40.7% |
| EPS Growth (YoY) | -188.5% |
| FCF Growth (YoY) | 295.2% |
| Price / Book | 22.58 |
| Price / Sales | 11.36 |
| FCF Yield | -4.3% |
| Altman Z-Score | 1.57 (distress) |
| Piotroski F-Score | 3/9 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
IONS overview · IONS earnings · IONS KPIs · IONS documents · IONS ownership · IONS peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.